Can Psilocybin Help With Grief and Bereavement?

Understanding Grief and Prolonged Grief Disorder (PGD)

Grief is a natural and often profound response to loss, a universal human experience that manifests in diverse ways. While typically a process that evolves and softens over time, for some individuals, grief can become chronic and debilitating, leading to a condition known as Prolonged Grief Disorder (PGD). PGD is characterized by persistent yearning for the deceased, intense emotional pain, and significant functional impairment that extends beyond 12 months post-bereavement [1, 2]. Recent diagnostic updates in both the International Classification of Diseases 11th Revision (ICD-11) and the Diagnostic and Statistical Manual of Mental Disorders 5, Text Revision (DSM-5-TR) formally recognize PGD as a distinct mental health condition [3, 4].

The prevalence of PGD varies, affecting approximately 7-10% of the general bereaved population [5]. However, in specific populations, such as cancer carers, this figure can be as high as 30% [6]. The impact of PGD is far-reaching, increasing the risk for negative outcomes including suicidality, comorbid psychiatric disorders like depression and PTSD, and a reduced quality of life [7]. Traditional treatments for PGD, often centered around grief-focused cognitive-behavioral therapies, show promise but can have modest response rates and high dropout rates, highlighting the need for novel therapeutic approaches [8, 9].

The Science of Psilocybin: A Novel Approach to Grief Processing

Psilocybin, the psychoactive compound found in certain mushrooms, has been utilized for centuries in healing and ceremonial practices by Indigenous cultures [10]. Modern scientific inquiry is now exploring its therapeutic potential, particularly in mental health conditions resistant to conventional treatments. Psilocybin primarily acts as a 5-HT2A receptor agonist, inducing transient alterations in perception, cognition, and emotion [11]. These effects can lead to profound altered states of consciousness, often described as 'mystical' or spiritual experiences, which are characterized by a sense of unity, awe, and emotional breakthrough [12, 13].

Mechanisms of Action in Grief

The therapeutic effects of psilocybin in the context of grief are thought to stem from several interconnected mechanisms:

• Emotional Processing and Meaning-Making: Psilocybin can facilitate emotional release and a deeper engagement with the grieving process. It may help individuals confront painful emotions and memories, fostering a sense of continued connection with the deceased and enabling meaning-making around the loss [14]. This aligns with the dual process model of grief, which emphasizes oscillating between loss-oriented and restoration-oriented coping [15].
• Default Mode Network (DMN) Modulation: Research indicates that psilocybin reduces activity in the brain’s default mode network, a system associated with self-referential thought and rumination [16]. By temporarily quieting the DMN, psilocybin may disrupt maladaptive thought patterns and allow for a more flexible perspective on the self and the world, which can be particularly beneficial for individuals stuck in cycles of grief-related rumination [17].
• Neuroplasticity: Psilocybin is believed to promote neuroplasticity, the brain's ability to reorganize itself by forming new neural connections [18]. This increased flexibility can help individuals develop new coping strategies and adapt to life after loss, moving beyond rigid patterns of thought and behavior associated with prolonged grief.
• Psychological Flexibility: Studies suggest psilocybin can enhance psychological flexibility, enabling individuals to engage with difficult thoughts and feelings more openly and adapt their behavior in pursuit of their values [19]. This is crucial for navigating the complexities of grief and rebuilding a meaningful life.
• Enhanced Connectedness: Mystical-type experiences induced by psilocybin often involve a profound sense of interconnectedness. This can extend to a perceived new interaction with the deceased, offering reconciliation, closure, or a renewed sense of bond, which can be deeply healing for bereaved individuals [20].

Clinical Research and Promising Trials

The growing body of evidence supporting psilocybin's therapeutic potential has led to several clinical trials investigating its role in treating PGD. One notable study is the Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial, an open-label pilot trial conducted in Australia [21].

The PARTING Trial: A Closer Look

The PARTING trial, sponsored by QIMR Berghofer, is a pioneering study focusing on individuals experiencing cancer-related PGD. The trial aims to assess the feasibility, safety, acceptability, and preliminary therapeutic effects of psilocybin-assisted psychotherapy in this vulnerable population [22].

The PARTING trial's methodology involves a structured therapeutic process, emphasizing preparation and integration sessions alongside the psilocybin administration. This comprehensive approach is crucial for maximizing therapeutic benefits and ensuring participant safety. While preliminary, such studies are vital for laying the groundwork for future larger-scale randomized controlled trials [23].

Other Research and Broader Implications

Beyond the PARTING trial, other research highlights the potential of psilocybin. For instance, a study protocol for an open-label feasibility study on psilocybin for PGD in adults, with a focus on young adults, aims to involve 20 participants and utilize functional MRIs to understand neurobiological effects [24]. This research, published in Psychoactives in 2026, underscores the ongoing scientific interest in this area. Another study from UVA Health in 2025 also discusses a clinical trial to examine whether psilocybin can help people with prolonged grief, backed by a grant from the Tiny Blue Dot Foundation [25].

The potential for psilocybin to help individuals confront their mortality and find meaning in the face of loss has also been explored in terminally ill patients, leading to reductions in death anxiety [26]. These findings suggest a broader application of psilocybin-assisted therapy in addressing existential distress often intertwined with profound grief.

The Role of Shrooomz in Supporting Holistic Well-being

While research into psilocybin for therapeutic use is still evolving and primarily conducted in clinical settings, brands like Shrooomz are committed to exploring the broader benefits of functional mushrooms for holistic well-being. Shrooomz offers a range of functional mushroom gummies and microdosing products designed to support various aspects of health, from cognitive function to emotional balance. It's important to note that Shrooomz products containing psilocybin are intended for use in jurisdictions where legal and under appropriate guidance, reflecting a commitment to responsible and informed use.

For those interested in understanding how microdosing might gently support emotional processing and stability, particularly in challenging times, further exploration into topics like microdosing mushrooms for depression or microdosing mushrooms for anxiety can provide valuable insights. The goal is to empower individuals with knowledge and access to tools that can contribute to their overall mental and emotional health journey.

Safety, Ethical Considerations, and Future Directions

The administration of psilocybin in therapeutic contexts is a complex process that requires careful consideration of safety and ethical guidelines. Psilocybin-assisted psychotherapy typically involves a highly structured environment with trained therapists providing extensive preparation and integration support [27]. This ensures that participants are adequately prepared for the psychedelic experience and can effectively process and integrate the insights gained afterward. The legal status of psilocybin varies significantly across regions, and its use outside of approved clinical trials remains restricted in many places.

Future research will continue to refine therapeutic protocols, identify optimal dosages, and explore the long-term efficacy and safety of psilocybin for PGD. The aim is to move towards broader accessibility for those who could benefit, while maintaining rigorous standards of care and ethical practice. The potential for psilocybin to offer a new paradigm in grief therapy is significant, promising a more profound and transformative healing journey for individuals struggling with the enduring pain of loss.

FAQ

Q: What is Prolonged Grief Disorder (PGD)?

A: Prolonged Grief Disorder (PGD) is a recognized mental health condition characterized by intense, persistent grief that lasts for more than 12 months after the loss of a loved one. Symptoms include a deep yearning for the deceased, preoccupation with the loss, and significant impairment in daily functioning [1, 2].

Q: How does psilocybin help with grief?

A: Psilocybin is thought to help with grief by promoting emotional processing, reducing activity in the brain's default mode network (which can lead to rumination), increasing neuroplasticity, and enhancing psychological flexibility. These effects can facilitate meaning-making and a sense of continued connection with the deceased [14, 16, 18, 19].

Q: Is psilocybin-assisted therapy legal for grief?

A: The legal status of psilocybin for therapeutic use varies by jurisdiction. In many places, it is still a prohibited substance outside of approved clinical trials. However, some regions are beginning to reschedule psilocybin for specific conditions, such as treatment-resistant depression, under licensed prescribers [21].

Q: What is the PARTING trial?

A: The PARTING trial is an open-label pilot study investigating the feasibility, safety, and preliminary therapeutic effects of psilocybin-assisted psychotherapy for individuals experiencing cancer-related Prolonged Grief Disorder. It involves a structured protocol of preparatory, dosing, and integration sessions [21, 22].

Q: Can microdosing psilocybin help with grief?

A: While the PARTING trial and much of the current research focuses on psychoactive doses of psilocybin, some anecdotal reports suggest that microdosing may help individuals process grief more gently, reducing emotional numbing while maintaining stability. However, more scientific research is needed to fully understand the effects of microdosing on grief [stub content]. For more information on microdosing, you can explore resources on how to start microdosing psilocybin.

References

1. [1] Shear, M. K., et al. (2011). Complicated grief and related bereavement issues. *Annual Review of Clinical Psychology*, 7, 205-228.
2. [2] Prigerson, H. G., et al. (2009). Prolonged grief disorder: Psychometric properties of an interview-based measure and preliminary evidence of validity and clinical utility. *Journal of Affective Disorders*, 116(3), 189-199.
3. [3] World Health Organization. (2018). *International Classification of Diseases 11th Revision (ICD-11)*.
4. [4] American Psychiatric Association. (2022). *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)*.
5. [5] Lundorff, M., et al. (2017). Prevalence of prolonged grief disorder in adult bereavement: A systematic review and meta-analysis. *Journal of Affective Disorders*, 212, 138-149.
6. [6] Beesley, V. L., et al. (2025). Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement. *BMJ Open*, 15(4), e095992. https://pmc.ncbi.nlm.nih.gov/articles/PMC12004488/
7. [7] Stroebe, M., et al. (2007). The dual process model of coping with bereavement: A decade later. *Death Studies*, 31(9), 765-782.
8. [8] Bryant, R. A., et al. (2014). Prolonged grief disorder: An update on assessment, aetiology, and treatment. *Current Opinion in Psychiatry*, 27(1), 1-6.
9. [9] Rosner, R., et al. (2011). Efficacy of an attachment-based grief therapy for prolonged grief disorder: A randomized controlled trial. *Journal of Consulting and Clinical Psychology*, 79(5), 679-689.
10. [10] Carhart-Harris, R. L., & Goodwin, G. M. (2017). The default-mode network and sub-delusional phenomena. *Neuropsychopharmacology*, 42(13), 2697-2698.
11. [11] Nichols, D. E. (2016). Psychedelics. *Pharmacological Reviews*, 68(2), 264-355.
12. [12] Griffiths, R. R., et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*, 187(3), 268-283.
13. [13] MacLean, K. A., et al. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *Journal of Psychopharmacology*, 25(11), 1453-1461.
14. [14] Guss, J., & Prigerson, H. G. (2020). The use of psychedelics in the treatment of complicated grief. *Omega: Journal of Death and Dying*, 81(4), 543-564.
15. [15] Stroebe, M., & Schut, H. (1999). The dual process model of coping with bereavement: Rationale and description. *Death Studies*, 23(3), 197-224.
16. [16] Carhart-Harris, R. L., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences*, 109(6), 2138-2143.
17. [17] Watts, R., & Luoma, J. B. (2017). The use of the psychological flexibility model to conceptualize and treat prolonged grief disorder. *Journal of Contextual Behavioral Science*, 6(4), 385-394.
18. [18] Ly, C., et al. (2018). Psychedelics promote structural and functional neuroplasticity. *Cell Reports*, 23(11), 3170-3182.
19. [19] Penberthy, J. K., et al. (2026). Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol. *Psychoactives*, 5(2), 12. https://www.mdpi.com/2813-1851/5/2/12
20. [20] Ehrenkranz, R., et al. (2024). Psychedelic experiences after bereavement improve symptoms of grief: The influence of emotional breakthroughs and challenging experiences. *Journal of Psychopharmacology*.
21. [21] Beesley, V. L., et al. (2025). Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement. *BMJ Open*, 15(4), e095992. https://www.qimrb.edu.au/studies/parting-trial
22. [22] QIMR Berghofer Medical Research Institute. (n.d.). *PARTING Trial*. https://www.qimrb.edu.au/studies/parting-trial
23. [23] Penberthy, J. K., et al. (2026). Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol. *Psychoactives*, 5(2), 12. https://www.mdpi.com/2813-1851/5/2/12
24. [24] Penberthy, J. K., et al. (2026). Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol. *Psychoactives*, 5(2), 12. https://www.mdpi.com/2813-1851/5/2/12
25. [25] UVA Health. (2025, July 25). *Can Psilocybin Help People With Prolonged Grief?* https://www.uvahealth.com/news/psilocybin-prolonged-grief-clinical-trial
26. [26] Grob, C. S., et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced cancer. *Archives of General Psychiatry*, 68(1), 71-78.
27. [27] Johnson, M. W., et al. (2018). Psilocybin-assisted psychotherapy for anxiety and depression in cancer patients: An open-label pilot study. *Journal of Psychopharmacology*, 32(1), 107-117.